ASCO’s Prostate Cancer Guidelines are Now Open for Public Comment

The American Society of Clinical Oncology (ASCO) has announced that the following guidelines, “Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update” and “Germline and Somatic Genomic Testing in Metastatic Prostate Cancer: ASCO Guideline” are now open for public comment.

The Metastatic Castration-Resistant Prostate Cancer Guideline, is an update to ASCO’s 2014 guideline, located here. This latest guideline incorporates new evidence to ensure the most current recommendations are provided.

As part of ASCO’s development process, they invite reviews and feedback for a 2-to 3-week period. Interested parties are encouraged to submit their comments here by September 6, 2024. Your input is invaluable in shaping the future of prostate cancer diagnosis and management.